SEC Form 4 · accession 0001209191-16-113501
Cascadian Therapeutics, Inc. · CASC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Dunseth Myers
Officer — President and CEO · Director
Period of report
Apr 4, 2016
Accepted (ET)
Apr 6, 2016 · 5:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001412067
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.18 | Apr 4, 2016 | A | 2,848,855 | A | — | Apr 4, 2024 | Common Stock | 2,848,855 | 2,848,855 | D |
Explanation of responses
- F1The option vests and is exercisable at the rate of 1/4th of the total shares on April 4, 2017 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on April 4, 2020.